Felbinac
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Felbinac: Brachyolmia-amelogenesis imperfecta syndrome
One-Sentence Summary
Felbinac is a topical NSAID (non-steroidal anti-inflammatory drug) originally used for osteoarthritis and related joint conditions. The TxGNN model predicts it may be effective for brachyolmia-amelogenesis imperfecta syndrome, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Brachyolmia-amelogenesis imperfecta syndrome |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Felbinac is known to be a topical NSAID that acts through COX inhibition, and its role in osteoarthritis is symptomatic relief of pain and inflammation.
Brachyolmia-amelogenesis imperfecta syndrome is a rare genetic skeletal and dental disorder, associated with LTBP3 variants that affect TGF-beta signalling. COX inhibition is not expected to act on this pathway, so no mechanistic link has been established. The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence or pharmacological rationale.
Other top-ranked predictions show the same pattern. Several are genetic skeletal conditions with no plausible NSAID target (acromesomelic dysplasia Hunter-Thompson type, brachyolmia, myosclerosis, combined immunodeficiency due to moesin deficiency). The more plausible ones are inflammatory joint diseases where NSAIDs give symptomatic relief only: spondyloarthropathy susceptibility, rheumatoid nodulosis, juvenile idiopathic arthritis and its RF-positive polyarticular subtype, and pseudoachondroplasia (where early joint pain and osteoarthritis occur). None has felbinac-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 88988 | Felbimax Gel (Lupin Ltd) | Tube of 30 gm Gel | Not stated |
Felbinac is available in India only as a topical gel.
Safety Considerations
Please refer to the package insert for safety information.
No drug interactions were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. There are no clinical trials or publications, and no mechanistic link between COX inhibition and the underlying biology of this genetic syndrome. A topical NSAID is also unlikely to be useful for a skeletal and dental disorder.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India Pharma source (a blocking gap for safety screening)
- Detailed mechanism of action data from DrugBank
- Any preclinical or clinical evidence linking felbinac to this syndrome
- Route-compatibility and disease-similarity assessments, which are still pending
- If a repurposing direction is wanted, consider the more plausible symptomatic candidates (spondyloarthropathy, juvenile idiopathic arthritis) for literature review first, with pediatric safety and dosing established for the JIA subtypes
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.